3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma
2
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms
1
Leiomyosarcoma
1
Inflammation
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Brain Neoplasms
1
Interventions
Doxorubicin
17
Cyclophosphamide
15
Ifosfamide
11
fludarabine
8
Radiotherapy
8
tazemetostat
5
pembrolizumab
4
pazopanib
4
Gemcitabine
4
pegfilgrastim
3
cixutumumab
3
Trabectedin
3
Radiation
3
Imatinib Mesylate
3
Filgrastim
3
Docetaxel
3
Dacarbazine
3
sargramostim
2
liposomal doxorubicin
2
fludarabine phosphate
2
brostallicin
2
aldesleukin
2
X-Rays
2
Sunitinib
2
Specimen Handling
2
Sorafenib
2
Radiation Dose Hypofractionation
2
Quality of Life
2
Nivolumab
2
Molecular Diagnostic Techniques
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma, Synovial
×
Tablets
×
Sarcoma
×
Clear all
NCT03016819
2026-02-25
APROMISS
Advenchen Laboratories, LLC
Phase 3
Recruiting
325 enrolled